Market research
CRBP Corbus Pharmaceuticals Holding
NASDAQ USD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 82M
- P/E ratio
- Not available
- Analyst target
- 35.8889
- Dividend yield
- Not available
- Beta
- 2.63
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 82M
- P/E ratio
- Not available
- Analyst target
- 35.8889
- Dividend yield
- Not available
- Beta
- 2.63
About
About Corbus Pharmaceuticals Holding
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
Research context
Corbus Pharmaceuticals Holding appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the CRBP discussion.
5 years, 6 months ago
Corbus Pharmaceuticals Holdings, Inc is currently in a long term downtrend where the price is trading 5.5% below its 200 day moving average.
From a valuation standpoint, the stock is 97.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 40.7.
Corbus Pharmaceuticals Holdings, Inc's total revenue sank by 74.4% to $658K since the same quarter in the previous year.
Its net income has increased by 67.6% to $-9M since the same quarter in the previous year.
Finally, its free cash flow grew by 23.4% to $-18M since the same quarter in the previous year.
Based on the above factors, Corbus Pharmaceuticals Holdings, Inc gets an overall score of 3/5.